Company Overview

Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Lead asset LB1148 is a Phase 3-ready protease inhibitor with potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo.

Latest Quarterly Earnings

Print Page
RSS Feeds
Email Alerts
Contact IR
Search